SI2831261T1 - A process for the production of low-level recombinant proteins DHNA (1,4-dihydroxy-2-naphthoate) - Google Patents

A process for the production of low-level recombinant proteins DHNA (1,4-dihydroxy-2-naphthoate) Download PDF

Info

Publication number
SI2831261T1
SI2831261T1 SI201330894T SI201330894T SI2831261T1 SI 2831261 T1 SI2831261 T1 SI 2831261T1 SI 201330894 T SI201330894 T SI 201330894T SI 201330894 T SI201330894 T SI 201330894T SI 2831261 T1 SI2831261 T1 SI 2831261T1
Authority
SI
Slovenia
Prior art keywords
recombinant protein
dhna
level
naphthoate
dihydroxy
Prior art date
Application number
SI201330894T
Other languages
English (en)
Slovenian (sl)
Inventor
Michael W. Laird
John Richard St.
Jane V. Gunson
Kim Kaleas
Deepa Nadarajah
Rachel Adams
Bradley R. Snedecor
Original Assignee
F.Hoffmann-La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche filed Critical F.Hoffmann-La Roche
Publication of SI2831261T1 publication Critical patent/SI2831261T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/40—Means for regulation, monitoring, measurement or control, e.g. flow regulation of pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/42—Means for regulation, monitoring, measurement or control, e.g. flow regulation of agitation speed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Sustainable Development (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SI201330894T 2012-03-27 2013-03-14 A process for the production of low-level recombinant proteins DHNA (1,4-dihydroxy-2-naphthoate) SI2831261T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261616297P 2012-03-27 2012-03-27
EP13713295.7A EP2831261B1 (en) 2012-03-27 2013-03-14 Method for producing recombinant proteins with low levels of DHNA (1,4-dihydroxy-2-naphthoate)
PCT/US2013/031383 WO2013148249A1 (en) 2012-03-27 2013-03-14 Improved harvest operations for recombinant proteins

Publications (1)

Publication Number Publication Date
SI2831261T1 true SI2831261T1 (en) 2018-01-31

Family

ID=48040433

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201330894T SI2831261T1 (en) 2012-03-27 2013-03-14 A process for the production of low-level recombinant proteins DHNA (1,4-dihydroxy-2-naphthoate)

Country Status (20)

Country Link
US (9) US20140080180A1 (enExample)
EP (1) EP2831261B1 (enExample)
JP (4) JP6225162B2 (enExample)
KR (2) KR20200037425A (enExample)
CN (2) CN109880867A (enExample)
AR (2) AR090340A1 (enExample)
AU (3) AU2013240280A1 (enExample)
BR (1) BR112014023176B1 (enExample)
CA (2) CA3086730A1 (enExample)
ES (1) ES2654424T3 (enExample)
HR (1) HRP20171966T1 (enExample)
IL (1) IL234377B (enExample)
MX (3) MX365947B (enExample)
MY (1) MY171729A (enExample)
PL (1) PL2831261T3 (enExample)
RU (2) RU2017139267A (enExample)
SG (4) SG10202007206WA (enExample)
SI (1) SI2831261T1 (enExample)
WO (1) WO2013148249A1 (enExample)
ZA (1) ZA201406434B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6201037B1 (en) 1986-01-28 2001-03-13 Ophthalmic Research Group International, Inc. Plastic lens composition and method for the production thereof
EP3469091A1 (en) 2016-06-10 2019-04-17 Lonza Ltd Method for stabilizing proteins
SG11201903605TA (en) * 2016-11-07 2019-05-30 Seattle Genetics Inc Distribution of engineered-cysteine caps
KR102825164B1 (ko) * 2018-03-27 2025-06-26 브리스톨-마이어스 스큅 컴퍼니 자외선 신호를 사용한 단백질 농도의 실시간 모니터링
PL3857237T3 (pl) * 2019-01-16 2023-07-10 Regeneron Pharmaceuticals, Inc. Sposoby charakteryzowania mostka disiarczkowego
CN109725088B (zh) * 2019-03-16 2021-05-18 丁立平 一种测定豆芽中2-萘甲酸及其衍生物的气相色谱-质谱联用法
CN110305903B (zh) * 2019-07-31 2021-10-01 江苏璟泽生物医药有限公司 重组人促卵泡激素及其制备方法
CN113155776A (zh) * 2021-04-29 2021-07-23 华东交通大学 一种柑桔最佳采收期预测方法
FR3146146A1 (fr) 2023-02-24 2024-08-30 Bgene Genetics Production d’acide 1-4-dihydroxy-2-naphtoïque par Escherichia coli

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2036891B (en) 1978-12-05 1983-05-05 Windsor Smith C Change speed gear
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1989012463A1 (en) 1988-06-21 1989-12-28 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK0602126T3 (da) 1991-08-14 2003-06-16 Genentech Inc Immunoglobulinvarianter til specifikke FC epsilon-receptorer
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5288931A (en) 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
AU687755B2 (en) 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP0733207B1 (en) 1993-12-10 1997-08-27 Genentech, Inc. Methods for diagnosis of allergy and screening of anti-allergy therapeutics
JP3825798B2 (ja) 1994-01-18 2006-09-27 ジェネンテク，インコーポレイテッド ＩｇＥアンタゴニストを用いる寄生虫感染症の治療法
US5702946A (en) 1994-03-03 1997-12-30 Genentech, Inc. Anti-IL-8 monoclonal antibodies for treatment of inflammatory disorders
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
ES2183131T3 (es) 1996-01-23 2003-03-16 Genentech Inc Anticuerpos anti-cd18 utilizados contra el ictus cerebral.
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
DK0941344T3 (da) 1996-11-27 2004-09-27 Genentech Inc Humaniserede anti-CD11a-antistoffer
IL132240A0 (en) 1997-04-07 2001-03-19 Genentech Inc Anti-vegf antibodies
EP1860187B1 (en) 1997-05-15 2011-07-13 Genentech, Inc. Apo-2 receptor
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
BR0015224A (pt) 1999-10-29 2002-07-09 Genentech Inc Anticorpo anti-antìgeno de célula estaminal prostática (psca) isolado, anticorpo monoclonal anti-psca, ácido nucleico isolado, vetor de expressão, célula, célula hospedeira, método de produção de anticorpo, composição método in vitro para matar uma célula cancerosa que expresse psca, uso de uma anticorpo monoclonal anti-psca e artigo industrializado
US6946271B2 (en) * 2000-09-20 2005-09-20 Degussa Ag Nucleotide sequences which code for the menE gene
US6979556B2 (en) 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
NZ543200A (en) * 2003-03-26 2009-01-31 Meiji Dairies Corp Method for stabilizing 1,4-dihydroxy-2-naphthoic acid
ATE353969T1 (de) * 2003-08-13 2007-03-15 Sandoz Ag Expressionsvektoren, transformierte wirtszellen und fermentationsverfahren zur herstellung rekombinanter polypeptide
JP4972412B2 (ja) * 2004-02-04 2012-07-11 メルク・シャープ・エンド・ドーム・コーポレイション Ｅ．コリ発酵によるプラスミドｄｎａの大規模生産のための方法
US7361764B2 (en) * 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
CN101115832A (zh) * 2004-11-26 2008-01-30 协和发酵工业株式会社 工业上有用的微生物
MX2008014150A (es) * 2006-05-05 2009-02-04 Gangagen Inc Actividades antimicrobianas derivadas de fago.
JP5305615B2 (ja) * 2006-06-05 2013-10-02 株式会社Ａｄｅｋａ メナキノンの新規生合成経路に関与するタンパク質の遺伝子群を利用したメナキノンの製造方法
SG162834A1 (en) * 2006-07-14 2010-07-29 Genentech Inc Refolding of recombinant proteins
HUE037162T2 (hu) * 2007-07-09 2018-08-28 Genentech Inc Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során
CN101665798B (zh) * 2008-09-06 2012-11-21 浙江我武生物科技股份有限公司 一种制备重组人血清白蛋白与干扰素α融合蛋白的方法
CN101503470A (zh) * 2008-09-27 2009-08-12 上海交通大学 rhDSL重组蛋白及其制备方法
JP2010088387A (ja) * 2008-10-10 2010-04-22 Waseda Univ 放線菌内で目的タンパク質を誘導発現可能なプロモーター

Also Published As

Publication number Publication date
RU2636353C2 (ru) 2017-11-22
BR112014023176B1 (pt) 2021-09-28
US20250137027A1 (en) 2025-05-01
CN109880867A (zh) 2019-06-14
SG10202007206WA (en) 2020-08-28
CN104350156A (zh) 2015-02-11
US20240158825A1 (en) 2024-05-16
MX365947B (es) 2019-06-19
RU2017139267A (ru) 2019-02-12
SG10201912877SA (en) 2020-02-27
KR20140148392A (ko) 2014-12-31
KR20200037425A (ko) 2020-04-08
EP2831261A1 (en) 2015-02-04
MX2019007032A (es) 2019-08-16
CA3086730A1 (en) 2013-10-03
JP2018046825A (ja) 2018-03-29
HK1207120A1 (en) 2016-01-22
JP2020202849A (ja) 2020-12-24
ES2654424T3 (es) 2018-02-13
JP2019141049A (ja) 2019-08-29
RU2014137554A (ru) 2016-05-20
IL234377B (en) 2021-01-31
CN104350156B (zh) 2019-04-02
US20150225760A1 (en) 2015-08-13
AU2017202484B2 (en) 2019-06-13
KR102096678B1 (ko) 2020-04-02
CA2866753A1 (en) 2013-10-03
SG11201406112TA (en) 2014-10-30
HRP20171966T1 (hr) 2018-02-09
AU2017202484A1 (en) 2017-05-04
MY171729A (en) 2019-10-25
SG10201508420VA (en) 2015-11-27
US20200199639A1 (en) 2020-06-25
AU2019226192A1 (en) 2019-09-26
JP6225162B2 (ja) 2017-11-01
CA2866753C (en) 2020-09-22
AR090340A1 (es) 2014-11-05
WO2013148249A1 (en) 2013-10-03
MX2014011558A (es) 2014-11-14
US20140080180A1 (en) 2014-03-20
US20160130624A1 (en) 2016-05-12
PL2831261T3 (pl) 2018-04-30
EP2831261B1 (en) 2017-10-18
BR112014023176A2 (pt) 2017-06-20
ZA201406434B (en) 2017-08-30
JP2015512259A (ja) 2015-04-27
US20230069966A1 (en) 2023-03-09
US20180291411A1 (en) 2018-10-11
MX2018007677A (es) 2020-11-12
AR116615A2 (es) 2021-05-26
AU2013240280A1 (en) 2014-10-16
US9765379B2 (en) 2017-09-19
US20210171997A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
De Luca et al. Downstream processing of therapeutic peptides by means of preparative liquid chromatography
Read et al. Process analytical technology (PAT) for biopharmaceutical products: Part I. Concepts and applications
HRP20171966T1 (hr) Postupak za proizvodnju rekombinantnih proteina s niskim razinama dhna (1,4-dihidroksi-2-naftoata)
Lavoie et al. Targeted capture of Chinese hamster ovary host cell proteins: Peptide ligand discovery
JP2015512259A5 (enExample)
WO2008005847A3 (en) Method of producing factor viii proteins by recombinant methods
Koehler et al. Pressure dependence of 15N chemical shifts in model peptides Ac-Gly-Gly-X-Ala-NH2
Andrade et al. An integrated approach to aggregate control for therapeutic bispecific antibodies using an improved three column mab platform‐like purification process
Jiang et al. Eco-innovation in reusing food by-products: Separation of ovalbumin from salted egg white using aqueous two-phase system of PEG 1000/(NH4) 2SO4
Abou-Diab et al. Bovine hemoglobin enzymatic hydrolysis by a new ecoefficient process—Part I: Feasibility of electrodialysis with bipolar membrane and production of neokyotorphin (α137-141)
Di Marco et al. Simultaneous monitoring of monoclonal antibody variants by strong cation-exchange chromatography hyphenated to mass spectrometry to assess quality attributes of rituximab-based biotherapeutics
Wei et al. iTRAQ-based proteomics analysis of serum proteins in Wistar rats treated with sodium fluoride: insight into the potential mechanism and candidate biomarkers of fluorosis
Liu et al. Challenges and strategies for a thorough characterization of antibody acidic charge variants
Song et al. Absence of Dx2 at Glu-D1 locus weakens gluten quality potentially regulated by expression of nitrogen metabolism enzymes and glutenin-related genes in wheat
Ribeiro et al. Proteogenomic characterization of novel x-type high molecular weight glutenin subunit 1Ax1. 1
Matsumoto et al. Chemical characterization of the water-soluble organic nitrogen in the maritime aerosol
Feroz et al. Assessing detergent‐mediated virus inactivation, protein stability, and impurity clearance in biologics downstream processes
Fitriani et al. Impact of gastrointestinal digestion simulation on the formation of angiotensin-I-converting enzyme inhibitory (ACE-I) peptides from germinated lamtoro gung flour
ATE474922T1 (de) Fluoreszenzproteine aus copepoda-spezies und verfahren zur verwendung davon
ATE509946T1 (de) Fluoreszenzproteine und chromoproteine aus nicht- aequorea-hydrozoa-spezies sowie verfahren zur verwendung davon
van Schaick et al. Native liquid chromatography and mass spectrometry to structurally and functionally characterize endo-xylanase proteoforms
Pan et al. Engineering batch and pulse refolding with transition of aggregation kinetics: an investigation using green fluorescent protein (GFP)
Paradela et al. Evaluation of isotope-coded protein labeling (ICPL) in the quantitative analysis of complex proteomes
Bosc-Bierne et al. Investigation of impurities in peptide pools
Zhang et al. Peptonics: A new family of cell‐protecting surfactants for the recombinant expression of therapeutic proteins in mammalian cell cultures